A5073396605- Bladder and Urothelial Cancer Treatments
- Fibroblast Growth Factor Research
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
- Esophageal Cancer Research and Treatment
- Conservation Techniques and Studies
- Building materials and conservation
- Monoclonal and Polyclonal Antibodies Research
- PI3K/AKT/mTOR signaling in cancer
- Structural Health Monitoring Techniques
- Cultural Heritage Materials Analysis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Middle East and Rwanda Conflicts
- Galectins and Cancer Biology
- Islamic Studies and History
- Urinary and Genital Oncology Studies
- Concrete Corrosion and Durability
- Cancer Cells and Metastasis
- Socioeconomic Development in MENA
- Urological Disorders and Treatments
- Genital Health and Disease
- Ubiquitin and proteasome pathways
Universitätsklinikum Würzburg
2024-2025
University of Würzburg
2023-2024
Universitätsmedizin Göttingen
2018-2024
Technical University of Darmstadt
2024
University of Göttingen
2017-2022
Museum of Art and Design Hamburg
2022
Nephrologisches Zentrum Goettingen
2019
Federal Institute For Materials Research and Testing
2013
Ruhr University Bochum
1997
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit only achieved in a small, yet uncharacterized patient subset. NECTIN4 located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) cancer. Here, we aimed to evaluate amplifications as genomic biomarker predict EV response mUC. MATERIALS AND METHODS We established NECTIN4-specific fluorescence...
673 Background: The anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit only achieved in a small, yet uncharacterized patient subset. NECTIN4 located on chromosome 1q23.3, and 1q23.3 gains are frequent genomic events mUC leading to amplifications. Here, we aimed evaluate the potential of amplification as biomarker predict EV response mUC. Methods: We established NECTIN4-specific...
Abstract Im Rahmen des Forschungsprojekts IDA‐KI wird eine Forschungsbrücke (openLAB) gebaut, die bis in den Bereich der starken Schädigung belastet wird. Begleitend werden umfangreiche Messungen und Untersuchungen durchgeführt somit einmalige Datenbasis für Validierung von Schadensdetektions‐ Auswertemethoden unter realen Umweltbedingungen am großmaßstäblichen Modell geschaffen. vorliegenden Beitrag Projektidee skizziert im Bau befindliche sowie das dort installierte Monitoringsystem...
Abstract Aberrations of the fibroblast growth factor receptor (FGFR) family members are frequently observed in metastatic urothelial cancer (mUC), and blocking FGF/FGFR signaling axis is used as a targeted therapeutic strategy for treating patients. Erdafitinib pan-FGFR inhibitor, which has recently been approved by FDA mUC with FGFR2/3 alterations. Although patients show initial response to erdafitinib, acquired resistance rapidly develops. Here, we found that adipocyte precursors promoted...
Zusammenfassung Die radikale Zystektomie eignet sich nicht für jeden Patienten mit muskelinvasivem Urothelkarzinom der Harnblase. Obwohl die multimodale primär organerhaltende Therapie in S3-Leitlinie zum Harnblasenkarzinom als Alternative aufgeführt zur radikalen wird, wird dieser Eingriff Deutschland im Vergleich zu anderen Ländern relativ selten durchgeführt. In diesem Artikel versucht, Verfahren miteinander vergleichen, um auf diese Art Indikation genauer stellen können und Praktiken...
Immune checkpoint blockade (IO) has revolutionised the treatment of metastatic renal cell carcinoma (mRCC). Early C-reactive protein (CRP) kinetics, especially recently introduced CRP flare-response phenomenon, shown promising results to predict IO efficacy in mRCC, but only been studied second line or later. Here, we aimed validate predictive value early kinetics for 1st-line mRCC with αPD-1 plus either αCTLA-4 (IO+IO) tyrosine kinase inhibitor (IO+TKI).In this multicentre retrospective...
Here we describe the establishment and characterization of an AR+, PSMA+, ERG+, PTEN-/-, CHD1+/- patient-derived xenograft (PDX) model termed 'C5', which has been developed from a 60 years old patient suffering castration-resistant prostate cancer (CRPC). The underwent radical prostatectomy, showed early tumor marker PSA recurrence and, one year after surgery, abiraterone resistance. Subcutaneous C5 tumors can be serially transplanted between mice grow within ~90 days to 1.5-2 cm³ in SCID...
Although biomarkers predicting therapy response in first-line metastatic renal carcinoma (mRCC) remain to be defined, C-reactive protein (CRP) kinetics have recently been associated with immunotherapy (IO) response. Here, we aimed assess the predictive and prognostic power of two contemporary CRP definitions a large, real-world mRCC cohort.Metastatic patients treated IO-based within 5 years were retrospectively included this multicentre study. According Fukuda et al., defined as 'CRP...
The aim of this study was to test for differences in overall (OS) and progression-free survival (PFS) rates toxicity first-line immune checkpoint inhibition (IO) combination therapy metastatic renal-cell carcinoma (mRCC) patients.Between November 2017 April 2021, 104 patients with histologically confirmed mRCC from 6 tertiary referral centers either IO + (nivolumab ipilimumab, n = 68) or tyrosine kinase inhibitor (TKI) (pembrolizumab axitinib, 36) were included. Kaplan-Meier Cox regression...
The majority of the objects found in textiles collection at German Historical Museum Berlin have been treated with different biocides various points past. Prior to this study, presence organochlorinated pesticides rooms and storage cabinets had already proven an analysis air samples that employed gas chromatography mass spectroscopy. To estimate risks these toxins pose both collections museum staff, we conducted a field study help portable X-ray fluorescence spectrometer. In present attempt...
It is unclear whether endoscopic assessment of the stone-free rate after flexible ureteroscopy (fURS) as effective with low-dose computed tomography (CT) scan.Prospective documentation patients kidney stones > 10 mm diameter from 2 different centers (Freiburg, Regensburg), who underwent fURS and were declared to be endoscopically completely stone-free. Low-dose CT control performed 4-8 weeks postoperatively.Thirty-eight treated between October 2015 August 2016 (12 F, 26 M). Average age was...
To mitigate infrastructure deterioration, structural health monitoring (SHM) has been employed for more than half a century, gaining momentum with recent advancements in information, communication, and sensing technologies. In particular, wireless sensor networks have gradually incorporated into SHM, offering new opportunities towards enhanced flexibility scalability, as compared to cable-based SHM systems. However, nodes are installed at fixed locations and, causing high installation costs,...
Focal therapies such as high-intensity focused ultrasound (HiFU) are an emerging therapeutic option for prostate cancer (PCA). Thermal or mechanical effects mediate most therapies. Moreover, locally administered drugs bicalutamide docetaxel new focal options. We assessed the impact of medical treatments on cell viability and heat sensitivity by pre-treating PCA lines then gradually exposing them to heat. The individual response tested differed largely. Vertebral-Cancer Prostate (VCaP) cells...
Abstract The outcome of prostate cancer (PCa) patients is highly variable and depends on whether or not distant metastases occur. Multiple chromosomal deletions have been linked to early tumor marker PSA recurrence (biochemical relapse, BCR) after radical prostatectomy (RP), but their potential role for metastasis formation largely unknown. Here, we specifically analyzed deletion the suppressor CHD1 (5q21) influences post-surgical risk loss directly contributes in vivo. By considering...
M&K Medien & Kommunikationswissenschaft , Seite 241 - 260